Anyway, there’s a lot to think about and take from these comments – manipulation is easy, and drama and vanity contaminates and creates distance and space for all sorts of dysfunctional behaviour. Some of this is gendered – women – on the whole – are at least ostensibly more interested in a serious relationship and tend to be more sensitive to outward judgment (and therefore more likely to approval-seek, engage in fantasy and be more easily malleable), but, once you know how to do it, it’s not that hard to use people, and, quite frankly, I have found the men I have dated in recent weeks to be ridiculously dramatic and worried about the future (and what things mean and what I think about them). In any case, I am with Grace, it’s essentially a human issue. Humans can be real sh*ts if they want to be.
Hi! I’m a 15 year old girl and I need help to understand my body. I’m 5″4 and about 130 pounds with quite an athletic/heavy built. I’ve been insecure about my weight for several years since I started ‘getting curves’ as a teenager, and for the last year I’ve been starving myself on and off but only losing a bit of fat and muscle mass. I’ve only now started to try and get healthier, and though calorie calculators say I should be eating around 2200 calories a day to keep my weight and at least 1200 to function, I never really eat more than 1000 a day. The thing is, I never think I have? I’m not a big eater and yet I have a lot of trouble with getting slimmer. Do I need to eat more?
A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was months in the nab-paclitaxel-gemcitabine group as compared with months in the gemcitabine group (hazard ratio for death, ; 95% confidence interval [CI], to ; P<). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was months in the nab-paclitaxel-gemcitabine group, as compared with months in the gemcitabine group (hazard ratio for disease progression or death, ; 95% CI, to ; P<); the response rate according to independent review was 23% versus 7% in the two groups (P<). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days.